SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Mental Disease

PUBLISHER: Market Glass, Inc. | PRODUCT CODE: 2148452

Cover Image

PUBLISHER: Market Glass, Inc. | PRODUCT CODE: 2148452

Narcolepsy Therapeutics

PUBLISHED:
PAGES: 257 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Team License: Up to 10 users)
USD 11115
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Narcolepsy Therapeutics Market to Reach US$6.4 Billion by 2032

The global market for Narcolepsy Therapeutics estimated at US$4.0 Billion in the year 2025, is expected to reach US$6.4 Billion by 2032, growing at a CAGR of 7.0% over the analysis period 2025-2032. Narcolepsy with Cataplexy Treatment, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$2.4 Billion by the end of the analysis period. Growth in the Narcolepsy without Cataplexy Treatment segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 10.4% CAGR

The Narcolepsy Therapeutics market in the U.S. is estimated at US$1.1 Billion in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2032 trailing a CAGR of 10.4% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Narcolepsy Therapeutics - Key Trends and Drivers

Narcolepsy therapeutics represent a critical area of medical research and treatment, addressing the needs of individuals afflicted by this chronic neurological disorder characterized by excessive daytime sleepiness, cataplexy, sleep paralysis, and hallucinations. The primary goal of narcolepsy treatment is to manage symptoms and improve patients' quality of life. Current therapeutic options include medications such as stimulants, sodium oxybate, and selective serotonin and norepinephrine reuptake inhibitors (SNRIs). Stimulants like modafinil and armodafinil help combat excessive daytime sleepiness by promoting wakefulness, while sodium oxybate is effective in reducing cataplexy and improving nighttime sleep. Additionally, SNRIs and other antidepressants are utilized to manage cataplexy and other associated symptoms. These medications, often used in combination, provide a tailored approach to treatment, reflecting the diverse manifestations of narcolepsy.

Recent advancements in narcolepsy therapeutics are significantly enhancing patient outcomes and expanding the treatment landscape. Innovations such as novel orexin receptor agonists are at the forefront of therapeutic development. Orexin, a neuropeptide that regulates wakefulness, is deficient in many individuals with narcolepsy, particularly those with type 1 narcolepsy. Orexin receptor agonists aim to mimic the action of orexin, thereby addressing the root cause of excessive sleepiness and cataplexy. Furthermore, advancements in genetic research and biomarker identification are paving the way for more precise and personalized treatment strategies. These developments not only enhance the efficacy of existing treatments but also contribute to the discovery of new therapeutic targets. The integration of digital health technologies, including mobile apps and wearable devices, is also playing a crucial role in managing narcolepsy. These technologies enable continuous monitoring of sleep patterns and medication adherence, providing valuable data that can be used to optimize treatment plans.

The growth in the narcolepsy therapeutics market is driven by several factors. Increasing awareness and diagnosis of narcolepsy are leading to a higher demand for effective treatments. Advancements in medical research, particularly in understanding the genetic and molecular basis of the disorder, are driving the development of innovative therapies. The rising prevalence of narcolepsy, coupled with improved healthcare infrastructure, is facilitating better access to diagnostic and therapeutic services. Additionally, the growing acceptance of personalized medicine is propelling the adoption of targeted therapies, which are tailored to individual patient profiles based on genetic and biomarker information. Pharmaceutical companies are investing heavily in research and development to bring new and more effective narcolepsy treatments to market. Regulatory support and the designation of orphan drug status for new narcolepsy medications are also incentivizing the development of novel therapeutics. Furthermore, patient advocacy groups are playing a crucial role in raising awareness, funding research, and supporting clinical trials, thereby contributing to market growth. These factors collectively underscore the dynamic and evolving nature of the narcolepsy therapeutics market, promising better outcomes for patients in the years to come.

SCOPE OF STUDY:

The report analyzes the Narcolepsy Therapeutics market by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment, Secondary Narcolepsy Treatment); Drug Class (Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class, Other Drug Classes)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

  • Arena Pharmaceuticals, Inc.
  • BioProjet Pharma
  • Graymark Healthcare, Inc.
  • Jazz Pharmaceuticals PLC
  • Ligand Pharmaceuticals, Inc.
  • Shionogi, Inc.
  • Shire PLC
  • Teva Pharmaceutical Industries Ltd.

WHAT SETS THIS REPORT APART FROM OTHERS?

Grounded in Domain Expert Perspectives - Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.

Captures Early Market Signals - Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.

Draws From a Broad, Validated Intelligence Base - Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.

Connects Signals With Strategic Market Direction - Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.

Provides In-Depth Company Intelligence - Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.

Market Share Is Examined Where It Matters - A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, Market Glass reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

Show more
Product Code: MG6594

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • Narcolepsy Therapeutics - Global Key Competitors Percentage Market Share in 2026 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 14 Players Worldwide in 2026 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness and Diagnosis of Narcolepsy Spurs Demand for Therapeutics
    • Advances in Genetic Research Throw the Spotlight on Personalized Narcolepsy Treatments
    • Innovations in Orexin Receptor Agonists Propel Growth in Narcolepsy Therapeutics Market
    • Integration of Digital Health Technologies Expands Addressable Market Opportunity
    • Improved Healthcare Infrastructure Strengthens Business Case for Narcolepsy Treatments
    • Pharmaceutical Investments in R&D Accelerate Development of Advanced Narcolepsy Drugs
    • Patient Advocacy Groups Drive Market Growth and Research Funding
    • Increasing Prevalence of Narcolepsy Generates Demand for Effective Treatment Options
    • Rising Acceptance of Personalized Medicine Throws the Spotlight on Targeted Therapies
    • Enhanced Understanding of Molecular Mechanisms Improves Treatment Efficacy
    • Early Diagnosis Techniques Strengthen Business Case for Comprehensive Treatment Plans
    • Expansion of Clinical Trials Accelerates New Therapeutic Approvals
    • Advances in Drug Delivery Systems Propel Growth in Narcolepsy Therapeutics Market
    • Global Initiatives and Funding for Sleep Disorders Research Drives Market Expansion
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Narcolepsy Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
    • TABLE 2: World Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 3: World Historic Review for Narcolepsy Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 4: World 13-Year Perspective for Narcolepsy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
    • TABLE 5: World Recent Past, Current & Future Analysis for Narcolepsy with Cataplexy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 6: World Historic Review for Narcolepsy with Cataplexy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 7: World 13-Year Perspective for Narcolepsy with Cataplexy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 8: World Recent Past, Current & Future Analysis for Narcolepsy without Cataplexy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 9: World Historic Review for Narcolepsy without Cataplexy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 10: World 13-Year Perspective for Narcolepsy without Cataplexy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 11: World Recent Past, Current & Future Analysis for Secondary Narcolepsy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 12: World Historic Review for Secondary Narcolepsy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 13: World 13-Year Perspective for Secondary Narcolepsy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 14: World Recent Past, Current & Future Analysis for Central Nervous System Stimulants Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 15: World Historic Review for Central Nervous System Stimulants Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 16: World 13-Year Perspective for Central Nervous System Stimulants Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 17: World Recent Past, Current & Future Analysis for Sodium Oxybate Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 18: World Historic Review for Sodium Oxybate Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 19: World 13-Year Perspective for Sodium Oxybate Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 20: World Recent Past, Current & Future Analysis for Selective Serotonin Reuptake Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 21: World Historic Review for Selective Serotonin Reuptake Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 22: World 13-Year Perspective for Selective Serotonin Reuptake Inhibitors Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 23: World Recent Past, Current & Future Analysis for Tricyclic Antidepressants Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 24: World Historic Review for Tricyclic Antidepressants Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 25: World 13-Year Perspective for Tricyclic Antidepressants Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 27: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 28: World 13-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032

III. MARKET ANALYSIS

  • UNITED STATES
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 30: USA Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 31: USA 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 32: USA Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 33: USA Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 34: USA 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 36: Canada Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 37: Canada 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 39: Canada Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 40: Canada 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • JAPAN
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 42: Japan Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 43: Japan 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 45: Japan Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 46: Japan 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • CHINA
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 48: China Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 49: China 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 50: China Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 51: China Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 52: China 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • EUROPE
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 54: Europe Historic Review for Narcolepsy Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 55: Europe 13-Year Perspective for Narcolepsy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 57: Europe Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 58: Europe 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 60: Europe Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 61: Europe 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • FRANCE
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 63: France Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 64: France 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 65: France Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 66: France Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 67: France 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • GERMANY
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 69: Germany Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 70: Germany 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 72: Germany Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 73: Germany 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 75: Italy Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 76: Italy 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 78: Italy Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 79: Italy 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • UNITED KINGDOM
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 81: UK Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 82: UK 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 83: UK Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 84: UK Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 85: UK 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 87: Spain Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 88: Spain 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 90: Spain Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 91: Spain 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 93: Russia Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 94: Russia 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 96: Russia Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 97: Russia 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 100: Rest of Europe 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 103: Rest of Europe 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • ASIA-PACIFIC
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Narcolepsy Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 106: Asia-Pacific 13-Year Perspective for Narcolepsy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 109: Asia-Pacific 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 112: Asia-Pacific 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • AUSTRALIA
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 114: Australia Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 115: Australia 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 117: Australia Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 118: Australia 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • INDIA
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 120: India Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 121: India 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 122: India Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 123: India Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 124: India 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 126: South Korea Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 127: South Korea 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 129: South Korea Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 130: South Korea 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • LATIN AMERICA
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 138: Latin America Historic Review for Narcolepsy Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 139: Latin America 13-Year Perspective for Narcolepsy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020, 2026 & 2032
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 141: Latin America Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 142: Latin America 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 144: Latin America Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 145: Latin America 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 147: Argentina Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 148: Argentina 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 150: Argentina Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 151: Argentina 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 153: Brazil Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 154: Brazil 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 156: Brazil Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 157: Brazil 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 159: Mexico Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 160: Mexico 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 162: Mexico Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 163: Mexico 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 166: Rest of Latin America 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 169: Rest of Latin America 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • MIDDLE EAST
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
    • TABLE 171: Middle East Historic Review for Narcolepsy Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 172: Middle East 13-Year Perspective for Narcolepsy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2020, 2026 & 2032
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 174: Middle East Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 175: Middle East 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 177: Middle East Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 178: Middle East 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 180: Iran Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 181: Iran 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 183: Iran Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 184: Iran 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 186: Israel Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 187: Israel 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 189: Israel Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 190: Israel 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 193: Saudi Arabia 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 196: Saudi Arabia 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 198: UAE Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 199: UAE 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 201: UAE Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 202: UAE 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 205: Rest of Middle East 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 208: Rest of Middle East 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • AFRICA
    • Narcolepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 210: Africa Historic Review for Narcolepsy Therapeutics by Treatment - Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 211: Africa 13-Year Perspective for Narcolepsy Therapeutics by Treatment - Percentage Breakdown of Value Sales for Narcolepsy with Cataplexy Treatment, Narcolepsy without Cataplexy Treatment and Secondary Narcolepsy Treatment for the Years 2020, 2026 & 2032
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
    • TABLE 213: Africa Historic Review for Narcolepsy Therapeutics by Drug Class - Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
    • TABLE 214: Africa 13-Year Perspective for Narcolepsy Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Central Nervous System Stimulants Drug Class, Sodium Oxybate Drug Class, Selective Serotonin Reuptake Inhibitors Drug Class, Tricyclic Antidepressants Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!